Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial

References

• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim J, Sondak V, Richards J, Flaherty L, Ernstoff M, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444–58
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001; 19(5)1430–6
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670–7
   PubMed Web of Science ®Google Scholar
• Creagan ET, Dalton RJ, Ahmann DL, Jung S-H, Morton RF, Langdon RM, Jr, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2776–83
   PubMed Web of Science ®Google Scholar
• Eggermont A. Adjuvant therapy in melanoma. Eur J Cancer 2003; 5(Suppl 1)S107
   Google Scholar
• Cascinelli N, Belli F, Mackie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon α-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001; 358: 866–9
   PubMed Web of Science ®Google Scholar
• Cameron DA, Cornbleet MC, Mackie RM, Hunter JAA, Gore M, Hancock B, et al. Adjuvant interferon alpha 2b in high risk melanoma–the Scottish study. Br J Cancer 2001; 84: 1146–9
   PubMed Web of Science ®Google Scholar
• Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905–10
   PubMed Web of Science ®Google Scholar
• Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16: 1425–9
   PubMed Web of Science ®Google Scholar
• Eggermont A, Punt C. Does adjuvant systemic therapy with Interferon-alpha for stage II–III melanoma prolong survival?. Am J Clin Dermatol 2003; 4: 531–6
   PubMedGoogle Scholar
• Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials. Cancer Treat Rev 2003; 4: 241–52
   Google Scholar
• Garbe, C, Hauschild, A, Linse, R, Dummer, A, Kapp, J, Ulrich, L, et al. Final results of two adjuvant trials of DeCOG. Proceedings of the 5th International Conference on the Adjuvant Therapy of Malignant Melanoma. 2004. pp 1–22.
   Google Scholar
• Eggermont AM, Kirkwood JM. Reevaluating the role of dacarbazine in metastatic melanoma: What have we learnt in 30 years?. Eur J Cancer 2004; 40: 1825–36
   PubMed Web of Science ®Google Scholar
• Rudolf Z, Furlan L. Adjuvant treatment of malignant melanoma with human leukocyte interferon. Period Biol 1990; 92: 141–2
   Google Scholar
• Fierlbeck G, Schreiner T, Rassner G. Combination of highly purified human leukocyte interferon α and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother 1995; 40: 157–64
   PubMedGoogle Scholar
• Foster GR, Finter NB. Are all type I interferons equivalent ?. J Viral Hepatitis 1998; 5: 143–52
   PubMedGoogle Scholar
• Ahrén B, Engman K, Lindblom A. Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte α-interferon. Anticancer Res 1992; 12: 881–4
   PubMedGoogle Scholar
• Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004; 172(7)4599–608
   PubMedGoogle Scholar
• Bruckner HW, Mokyr MB, Mitchell MS. Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma. Cancer Res 1974; 34: 181–3
   PubMed Web of Science ®Google Scholar
• Konjevic G, Jovic V, Radulovic S, Jelic S, Dzodic R, Spuzic I. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha. Neoplasma 2001; 48: 175–81
   PubMedGoogle Scholar
• Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol Today 1996; 17: 369–72
   PubMedGoogle Scholar
• Gogas, H, Ioannovich, J, Frangia, K, Tsoutsos, D, Panagiotou, P, Economou, TH, et al. The prevalence of of autoantibodies in patients with high risk melanoma receiving adjuvant interferon. Proceedings of the 5th International Conference on the Adjuvant Treatment of Malignant Melanoma. 2004. pp 1–11.
   Google Scholar
• Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74: 670–6
   PubMed Web of Science ®Google Scholar